Therapeutic Product Detail

Dolutegravir 2-Desfluoro Impurity

Explore technical data, documentation access, molecular information and enquiry options for this Clearsynth research product.

Product Code: CS-T-74004 Therapeutic Research Use Only
Dolutegravir 2-Desfluoro Impurity
Category
Therapeutic
API Family
Dolutegravir
Product Code
CS-T-74004
Research Status
For Laboratory Use

Dolutegravir 2-Desfluoro Impurity

Dolutegravir Therapeutic
Stock Status: In Stock
Live

CAT No.
CS-T-74004
CAS No.
1863916-88-4
Molecular Formula
C20H20FN3O5
Molecular Weight
401.39
Login to view price
There is no hazardous surcharge associated with this product.
There is no packaging charge associated with this product.
For Research Purposes only. Not for Personal or Veterinary use.
All compounds supplied are strictly intended for laboratory, research, analytical, and scientific use only. They are not meant for human consumption, therapeutic use, or any form of clinical application.
CAS No.
1863916-88-4
Product Code
CS-T-74004
M.F.
C20H20FN3O5
M.W.
401.39
Smiles
O=C(C1=CN(C2=C(O)C1=O)C[C@]3([H])OCC[C@@H](C)N3C2=O)NCC4=CC=C(F)C=C4
Category
Therapeutic
API Family
Dolutegravir
Storage Condition
Store at refrigerator (2-8°C) for long term storage
IUPAC Name
(4R,12aS)-N-(4-Fluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
References
Synonyms
Dolutegravir 2-Desfluoro Impurity
Application Notes
Defluoro Dolutegravir is an impurity of Dolutegravir, a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.
Purity by HPLC
99.46%
Hazard Compound
Refer MSDS for accurate information.
Overview
Defluoro Dolutegravir is an impurity of Dolutegravir, a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.

Refund Policy

We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of material handover. We have invested in the highest quality packaging materials and use international logistics partners to service our customers. If there is an issue with one or more of our products, it must be reported to us within 45 days of your receiving shipment for refund or account credit eligibility.

Downloading MSDS…
Quick Enquiry Email Us
Quick Enquiry
Tell us what you need
Quote Basket
Selected RFQ Items
Your RFQ basket is empty. Add a product block or copy a guided requirement here.